ES2148799T3 - Anticuerpos monoclonales neutralizantes contra virus sincitial respiratorio. - Google Patents
Anticuerpos monoclonales neutralizantes contra virus sincitial respiratorio.Info
- Publication number
- ES2148799T3 ES2148799T3 ES96933810T ES96933810T ES2148799T3 ES 2148799 T3 ES2148799 T3 ES 2148799T3 ES 96933810 T ES96933810 T ES 96933810T ES 96933810 T ES96933810 T ES 96933810T ES 2148799 T3 ES2148799 T3 ES 2148799T3
- Authority
- ES
- Spain
- Prior art keywords
- antibodies
- sincitial
- virus
- against respiratory
- monoclonal antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 230000000241 respiratory effect Effects 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 238000010367 cloning Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1006—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against or targeting material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Optics & Photonics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A LA IDENTIFICACION Y CLONAJE DE UN NUEVO ANTICUERPO MONOCLONAL HUMANO NEUTRALIZANTE FRENTE AL VIRUS RESPIRATORIO SINCITIAL. LA INVENCION APORTA DICHOS ANTICUERPOS, FRAGMENTOS DE DICHOS ANTICUERPOS QUE RETIENEN LA CAPACIDAD DE UNIRSE AL VRS, ANTICUERPOS QUIMERICOS QUE RETIENEN LA CAPACIDAD DE UNIRSE AL VRS Y COMPOSICIONES FARMACEUTICAS QUE INCLUYEN TALES ANTICUERPOS. LA INVENCION APORTA TAMBIEN EL AISLAMIENTO DE ACIDOS NUCLEICOS QUE CODIFICAN LOS ANTICUERPOS DE LA INVENCION Y CELULAS HUESPED TRANSFORMADAS CON ELLOS. FINALMENTE, LA INVENCION APORTA METODOS DIAGNOSTICOS Y TERAPEUTICOS QUE EMPLEAN LOS ANTICUERPOS Y ACIDOS NUCLEICOS DE LA INVENCION.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US393195P | 1995-09-18 | 1995-09-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2148799T3 true ES2148799T3 (es) | 2000-10-16 |
Family
ID=21708285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96933810T Expired - Lifetime ES2148799T3 (es) | 1995-09-18 | 1996-09-18 | Anticuerpos monoclonales neutralizantes contra virus sincitial respiratorio. |
Country Status (11)
Country | Link |
---|---|
US (3) | US7488477B2 (es) |
EP (2) | EP0851924A1 (es) |
AT (1) | ATE194291T1 (es) |
AU (2) | AU7075496A (es) |
CA (2) | CA2230116A1 (es) |
DE (1) | DE69609188T2 (es) |
DK (1) | DK0853487T3 (es) |
ES (1) | ES2148799T3 (es) |
GR (1) | GR3034349T3 (es) |
PT (1) | PT853487E (es) |
WO (2) | WO1997011177A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE474854T1 (de) * | 2000-01-27 | 2010-08-15 | Medimmune Llc | Rsv neutralisierende antikörper mit sehr hohen affinität |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
CA2401652A1 (en) * | 2000-03-01 | 2001-09-07 | Medimmune, Inc. | High potency recombinant antibodies and method for producing them |
US7179900B2 (en) * | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
CA2505316C (en) | 2002-11-08 | 2014-08-05 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
GB2398783A (en) * | 2003-02-26 | 2004-09-01 | Antonio Lanzavecchia | A method for producing immortalised human B memory lymphocytes |
GB0306618D0 (en) * | 2003-03-22 | 2003-04-30 | Univ Newcastle | Antibody |
US20100111856A1 (en) * | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
BRPI0516284A (pt) * | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
US20060115485A1 (en) * | 2004-10-29 | 2006-06-01 | Medimmune, Inc. | Methods of preventing and treating RSV infections and related conditions |
CA2678628A1 (en) | 2007-03-06 | 2008-09-12 | Symphogen A/S | Recombinant antibodies for treatment of respiratory syncytial virus infections |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
EP2201040A1 (en) * | 2007-09-24 | 2010-06-30 | Vanderbilt University | Monoclonal antibodies to respiratory syncytial virus and uses thereof |
WO2009052249A1 (en) * | 2007-10-19 | 2009-04-23 | Genentech, Inc. | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
KR100938998B1 (ko) * | 2008-01-08 | 2010-01-28 | (주) 에이프로젠 | 호흡기 신시티움 바이러스에 대한 항체 |
US8591961B2 (en) | 2008-09-04 | 2013-11-26 | Allergan, Inc. | Aesthetic treatment of scars and aging skin |
MX2012001882A (es) | 2009-08-13 | 2012-04-11 | Crucell Holland Bv | Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso. |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
KR101839163B1 (ko) | 2010-06-08 | 2018-03-15 | 제넨테크, 인크. | 시스테인 조작된 항체 및 접합체 |
CN103097412B (zh) | 2010-07-09 | 2016-08-10 | 克鲁塞尔荷兰公司 | 抗人呼吸道合胞病毒(rsv)抗体以及使用方法 |
TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法 |
CN107108724A (zh) | 2014-09-12 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 半胱氨酸改造抗体和缀合物 |
JO3555B1 (ar) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري |
EA039222B1 (ru) * | 2016-07-27 | 2021-12-20 | Мерк Шарп И Доум Корп. | Антитело, нейтрализующее респираторно-синцитиальный вирус человека |
WO2018075378A1 (en) * | 2016-10-17 | 2018-04-26 | Vanderbilt University | Human respiratory syncytial virus antibodies and methods of use therefor |
US11485775B2 (en) | 2016-10-21 | 2022-11-01 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
US11479600B2 (en) | 2016-10-21 | 2022-10-25 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
BR112019008063A2 (pt) | 2016-10-21 | 2019-07-02 | Adimab Llc | anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso |
TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
CA3060581A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
BR112020015588A2 (pt) * | 2018-01-31 | 2021-01-05 | The Wistar Institute Of Anatomy And Biology | Molécula de ácido nucleico codificando um ou mais anticorpos sintéticos, composição, anticorpo monoclonal anti-rsv, método para prevenir ou tratar uma doença, e, formulação. |
WO2021202463A1 (en) | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Anti-rsv antibodies |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4800078A (en) * | 1987-05-28 | 1989-01-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb |
GB9019812D0 (en) * | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
GB9207479D0 (en) * | 1992-04-06 | 1992-05-20 | Scotgen Ltd | Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man |
ES2191016T3 (es) * | 1992-09-16 | 2003-09-01 | Scripps Research Inst | Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial. |
AU3660893A (en) * | 1993-01-29 | 1994-08-15 | Med Immune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
CA2168349A1 (en) * | 1993-07-30 | 1995-02-09 | Lingxun Duan | Intracellular immunization |
AU689489B2 (en) * | 1993-07-30 | 1998-04-02 | Oravax, Inc | Monoclonal IgA antibody against respiratory syncytial virus |
-
1996
- 1996-09-18 WO PCT/US1996/014944 patent/WO1997011177A1/en not_active Application Discontinuation
- 1996-09-18 EP EP96931633A patent/EP0851924A1/en not_active Withdrawn
- 1996-09-18 CA CA002230116A patent/CA2230116A1/en not_active Abandoned
- 1996-09-18 AU AU70754/96A patent/AU7075496A/en not_active Abandoned
- 1996-09-18 CA CA002230127A patent/CA2230127A1/en not_active Abandoned
- 1996-09-18 ES ES96933810T patent/ES2148799T3/es not_active Expired - Lifetime
- 1996-09-18 WO PCT/US1996/014937 patent/WO1997010846A1/en active IP Right Grant
- 1996-09-18 PT PT96933810T patent/PT853487E/pt unknown
- 1996-09-18 DK DK96933810T patent/DK0853487T3/da active
- 1996-09-18 AU AU72400/96A patent/AU7240096A/en not_active Abandoned
- 1996-09-18 AT AT96933810T patent/ATE194291T1/de active
- 1996-09-18 DE DE69609188T patent/DE69609188T2/de not_active Expired - Fee Related
- 1996-09-18 EP EP96933810A patent/EP0853487B1/en not_active Expired - Lifetime
-
2000
- 2000-09-06 GR GR20000402037T patent/GR3034349T3/el not_active IP Right Cessation
-
2003
- 2003-04-30 US US10/425,855 patent/US7488477B2/en not_active Expired - Fee Related
-
2008
- 2008-04-24 US US12/082,000 patent/US20090110684A1/en not_active Abandoned
-
2011
- 2011-09-30 US US13/250,357 patent/US8221759B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
GR3034349T3 (en) | 2000-12-29 |
EP0853487A1 (en) | 1998-07-22 |
WO1997011177A1 (en) | 1997-03-27 |
US20120087909A1 (en) | 2012-04-12 |
PT853487E (pt) | 2000-11-30 |
US20040005324A1 (en) | 2004-01-08 |
CA2230116A1 (en) | 1997-03-27 |
ATE194291T1 (de) | 2000-07-15 |
US20090110684A1 (en) | 2009-04-30 |
DK0853487T3 (da) | 2000-10-23 |
EP0851924A1 (en) | 1998-07-08 |
WO1997010846A1 (en) | 1997-03-27 |
US8221759B2 (en) | 2012-07-17 |
DE69609188T2 (de) | 2000-12-21 |
CA2230127A1 (en) | 1997-03-27 |
EP0853487B1 (en) | 2000-07-05 |
AU7075496A (en) | 1997-04-09 |
AU7240096A (en) | 1997-04-09 |
US7488477B2 (en) | 2009-02-10 |
DE69609188D1 (de) | 2000-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2148799T3 (es) | Anticuerpos monoclonales neutralizantes contra virus sincitial respiratorio. | |
Wang et al. | Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection | |
Valkenburg et al. | IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection | |
BRPI0412245A (pt) | anticorpos de rg1 e usos destes | |
SE0103754L (sv) | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid | |
ES2133477T3 (es) | Forma de dosificacion que comprende un antigeno y una forma salina de un derivado de acido organico de un esterol. | |
AR003423A1 (es) | Anticuerpos monoclonales humanos de alta afinidad especificos de la proteina- f del rsv, celulas eucarioticas transfectadas; secuencia de adn y vector de expresion que lo codifican; metodo que utiliza los anticuerpos; una composicion farmaceutica que los contiene; metodo para detectar rsv y un kit de ensayo. | |
HUP0402048A2 (hu) | Eljárás specifikus patogének antigénjeinek azonosítására, izolálására és előállítására | |
DE69332518T2 (de) | Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung | |
TR199801722T2 (xx) | Peptit imm�nojenler. | |
KR900700508A (ko) | 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질 | |
BR0211296A (pt) | Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado | |
AU2003244855A1 (en) | Method to enhance an immune response of nucleic acid vaccination | |
BRPI0408779A (pt) | uso de composições, composição imunogênica e kit | |
Bennett et al. | DNA vaccination protects against botulinum neurotoxin type F | |
Zhang et al. | Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate | |
DE69734974D1 (de) | Verfahren zur transformation dendritischer zellen und aktivierung von t zellen | |
Ghaemi et al. | Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity | |
HUP0001458A2 (hu) | Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása | |
CN107530417A (zh) | H1n1流感的计算优化的广泛反应性抗原的协同共同给药 | |
Mosa et al. | A bivalent HCV peptide vaccine elicits pan-genotypic neutralizing antibodies in mice | |
ATE444310T1 (de) | Antiidiotypische antikörper die hiv-1 neutralisierende antikörper induzieren | |
CN104306995B (zh) | 一种抗j亚群禽白血病病毒感染的表位疫苗及其制备方法和应用 | |
Shalash et al. | The potential of developing a protective peptide‐based vaccines against SARS‐CoV‐2 | |
ES2085163T3 (es) | Vacunas contra los parasitos metazoos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 853487 Country of ref document: ES |